Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Bofanglutide

Stage Phase 3Stale

Sponsor Gan & Lee Pharmaceuticals

Route injection

Class GLP-1 RA

Mechanism biweekly GLP-1 receptor agonist

Sources

registry, as of 2025-11-25Stale

https://clinicaltrials.gov/study/NCT06728124

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 630. Conditions Obesity/Overweight. This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study in adult obese/overweight subjects in China to evaluate the efficacy and safety of GZR18 Injection in the subjects.

ClinicalTrials.gov NCT06728124 protocol and results modules

registry, as of 2026-03-11Stale

https://clinicaltrials.gov/study/NCT07292441

Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss. Overall status RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 500. Conditions Overweight or Obesity. This is a Phase 3 extension study conducted in subjects who have received GZR18 Injection once every 2 weeks (Q2W) for weight loss treatment for 52 weeks, aiming to explore the effect and safety of continuous injection of GZR18 Injection once every 4 weeks (Q4W) for 24 weeks on b

ClinicalTrials.gov NCT07292441 protocol and results modules

registry, as of 2025-11-25Stale

https://clinicaltrials.gov/study/NCT07150975

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects. Overall status RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 420. Conditions Obesity/Overweight in Adult. This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate the efficacy and safety of GZR18 Injection in this

ClinicalTrials.gov NCT07150975 protocol and results modules

registry, as of 2026-03-27Stale

https://clinicaltrials.gov/study/NCT07493057

Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 140. Conditions Obstructive Sleep Apnea (OSA). This study is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of GZR18 injection in obese subjects with moderate to severe obstructive sleep apnea who are unable or unwilling to undergo positive air

ClinicalTrials.gov NCT07493057 protocol and results modules

registry, as of 2026-04-03Stale

https://clinicaltrials.gov/study/NCT07501832

Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Gan & Lee Pharmaceuticals.. Enrollment 140. Conditions Obstructive Sleep Apnea (OSA). The study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of GZR18 injection in Chinese adult obese patients with moderate-to-severe obstructive sleep apnea (OSA) who are currently using p

ClinicalTrials.gov NCT07501832 protocol and results modules

registry, as of 2025-10-01Stale

https://clinicaltrials.gov/study/NCT06256562

A Study of GZR18 Injection in Obese/Overweight Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gan and Lee Pharmaceuticals, USA. Enrollment 340. Conditions Obesity; Overweight. This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.

ClinicalTrials.gov NCT06256562 protocol and results modules

registry, as of 2026-07-16Stale

https://clinicaltrials.gov/study/NCT06737042

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants. Overall status COMPLETED. Phases PHASE2. Lead sponsor Gan and Lee Pharmaceuticals, USA. Enrollment 326. Conditions Obesity and Overweight. This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The study will evaluate weight management in participants with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with weight-

ClinicalTrials.gov NCT06737042 protocol and results modules

registry, as of 2024-02-23Stale

https://clinicaltrials.gov/study/NCT06256536

A Study of GZR18 Injection in Chinese Obese/Overweight Patients. Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Gan and Lee Pharmaceuticals, USA. Enrollment 60. Conditions Obesity; Overweight. The study was a multicenter, randomized, double-blind, placebo-controlled phase Ib/IIa clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of GZR18 injection in Chinese adult obese/overweight patients. This study is divided into Part A and Part B, w

ClinicalTrials.gov NCT06256536 protocol and results modules

publication, as of 2026-07-10Stale

https://pubmed.ncbi.nlm.nih.gov/41760612/

overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Bofanglutide is a novel biweekly (once every two weeks; Q2W) glucagon-like peptide-1 receptor agonist. We evaluated the efficacy and safety of bofanglutide in Chinese adults with overweight or obesity in a random

PMID 41760612

Studies

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects

Registry NCT06728124

Phase Phase 3

Status Active, not recruiting

Enrollment 630

Start 2024-12-30

GZR18

Comparator placebo

Population Obesity/Overweight

Placebo

Population Obesity/Overweight

GZR18-BWM-303

Registry NCT07292441

Phase Phase 3

Status Recruiting

Enrollment 500

Start 2026-01-22

Placebo

Regimen every 4 weeks

Weeks 2

Population Overweight or Obesity

GZR18 injection Dose1

Regimen every 4 weeks

Weeks 2

Comparator placebo

Population Overweight or Obesity

GZR18 injection Dose2

Regimen every 4 weeks

Weeks 2

Comparator placebo

Population Overweight or Obesity

GZR18 injection Dose3

Regimen every 4 weeks

Weeks 2

Comparator placebo

Population Overweight or Obesity

Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects

Registry NCT07150975

Phase Phase 3

Status Recruiting

Enrollment 420

Start 2025-09-23

Primary completion 2027-06-30

Study completion 2027-06-30

Catalyst Primary completion. 2027-06-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

GZR18 Dose Level 1

Population Obesity/Overweight in Adult

GZR18 Dose Level 2

Population Obesity/Overweight in Adult

Semaglutide(Wegovy® )2.4 mg

Dose 2.4 mg

Population Obesity/Overweight in Adult

Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy

Registry NCT07493057

Phase Phase 3

Status Not yet recruiting

Enrollment 140

Start 2026-04-27

Primary completion 2027-11-14

Study completion 2027-11-14

Catalyst Primary completion. 2027-11-14. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

GZR18 injection

Comparator placebo

Population Obstructive Sleep Apnea (OSA)

Placebo

Population Obstructive Sleep Apnea (OSA)

Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy

Registry NCT07501832

Phase Phase 3

Status Not yet recruiting

Enrollment 140

Start 2026-03-27

Primary completion 2028-09-28

Study completion 2028-09-28

Catalyst Primary completion. 2028-09-28. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

GZR18 injection

Comparator placebo

Population Obstructive Sleep Apnea (OSA)

Placebo

Population Obstructive Sleep Apnea (OSA)

A Study of GZR18 Injection in Obese/Overweight Patients

Registry NCT06256562

Phase Phase 2

Status Completed

Enrollment 340

Start 2023-06-08

Primary completion 2024-06-05

Study completion 2024-06-05

GZR18

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Registry NCT06737042

Phase Phase 2

Status Completed

Enrollment 326

Start 2025-02-24

Primary completion 2026-02-27

Study completion 2026-02-27

Catalyst Primary completion. 2026-02-27. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

24 mg GZR18 group

Dose 24 mg

Population Obesity and Overweight

36 mg GZR18 group

Dose 36 mg

Population Obesity and Overweight

48 mg GZR18 group

Dose 48 mg

Population Obesity and Overweight

Tirzepatide group

Population Obesity and Overweight

A Study of GZR18 Injection in Chinese Obese/Overweight Patients

Registry NCT06256536

Phase Phase 1/2

Status Completed

Enrollment 60

Start 2022-07-14

Primary completion 2023-10-22

Study completion 2023-10-22

GZR18

Comparator placebo

Population Obesity; Overweight

Placebo

Population Obesity; Overweight